Basic helix-loop-helix transcription factor scleraxis (SCX)

Basic helix-loop-helix transcription factor scleraxis (SCX) is a crucial regulator of connective tissue development, specifically required for the specification and differentiation of tenocytes and ligamentocytes. It acts as a master transcription factor that binds to E-box sequences in the promoters of genes such as collagen type I and tenomodulin, thereby controlling the assembly and maintenance of the extracellular matrix (Uniprot, Q7RTU7). In addition to its role in development, SCX is a primary mediator of pathological fibrosis in the heart and other organs. Following myocardial injury, TGF-beta signaling induces SCX expression, which drives the phenotypic conversion of fibroblasts into myofibroblasts, leading to excessive collagen deposition and cardiac stiffness (PubMed, 22692646). Due to its central role in fibrotic signaling, SCX is regarded as a high-value therapeutic target for treating heart failure and chronic tendon injuries (PubMed, 31189078). While transcription factors are traditionally challenging to target with small molecules, current research explores the use of gene-silencing technologies and upstream pathway inhibitors to modulate SCX activity in clinical settings.

Other names

SCXbHLHe7Scleraxis homologClass E basic helix-loop-helix protein 7

Indirect inhibition via the TGF-beta/Smad signaling pathway or potential direct transcriptional modulation to reduce collagen synthesis and myofibroblast activity.